316 related articles for article (PubMed ID: 33388421)
1. Cancer-secreted exosomal miR-1468-5p promotes tumor immune escape via the immunosuppressive reprogramming of lymphatic vessels.
Zhou C; Wei W; Ma J; Yang Y; Liang L; Zhang Y; Wang Z; Chen X; Huang L; Wang W; Wu S
Mol Ther; 2021 Apr; 29(4):1512-1528. PubMed ID: 33388421
[TBL] [Abstract][Full Text] [Related]
2. Exosome-derived miR-142-5p remodels lymphatic vessels and induces IDO to promote immune privilege in the tumour microenvironment.
Zhou C; Zhang Y; Yan R; Huang L; Mellor AL; Yang Y; Chen X; Wei W; Wu X; Yu L; Liang L; Zhang D; Wu S; Wang W
Cell Death Differ; 2021 Feb; 28(2):715-729. PubMed ID: 32929219
[TBL] [Abstract][Full Text] [Related]
3. Melanoma cell-secreted exosomal miR-155-5p induce proangiogenic switch of cancer-associated fibroblasts via SOCS1/JAK2/STAT3 signaling pathway.
Zhou X; Yan T; Huang C; Xu Z; Wang L; Jiang E; Wang H; Chen Y; Liu K; Shao Z; Shang Z
J Exp Clin Cancer Res; 2018 Oct; 37(1):242. PubMed ID: 30285793
[TBL] [Abstract][Full Text] [Related]
4. Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages.
Yao X; Tu Y; Xu Y; Guo Y; Yao F; Zhang X
J Cell Mol Med; 2020 Sep; 24(17):9560-9573. PubMed ID: 32672418
[TBL] [Abstract][Full Text] [Related]
5. Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1.
Zhou CF; Ma J; Huang L; Yi HY; Zhang YM; Wu XG; Yan RM; Liang L; Zhong M; Yu YH; Wu S; Wang W
Oncogene; 2019 Feb; 38(8):1256-1268. PubMed ID: 30254211
[TBL] [Abstract][Full Text] [Related]
6. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
[TBL] [Abstract][Full Text] [Related]
7. miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer.
Wang C; Li X; Zhang L; Chen Y; Dong R; Zhang J; Zhao J; Guo X; Yang G; Li Y; Gu C; Xi Q; Zhang R
Int Immunopharmacol; 2021 Aug; 97():107822. PubMed ID: 34098485
[TBL] [Abstract][Full Text] [Related]
8. Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells.
Yoshimura A; Sawada K; Nakamura K; Kinose Y; Nakatsuka E; Kobayashi M; Miyamoto M; Ishida K; Matsumoto Y; Kodama M; Hashimoto K; Mabuchi S; Kimura T
BMC Cancer; 2018 Nov; 18(1):1065. PubMed ID: 30396333
[TBL] [Abstract][Full Text] [Related]
9. Maintenance of cancer stemness by miR-196b-5p contributes to chemoresistance of colorectal cancer cells via activating STAT3 signaling pathway.
Ren D; Lin B; Zhang X; Peng Y; Ye Z; Ma Y; Liang Y; Cao L; Li X; Li R; Sun L; Liu Q; Wu J; Zhou K; Zeng J
Oncotarget; 2017 Jul; 8(30):49807-49823. PubMed ID: 28591704
[TBL] [Abstract][Full Text] [Related]
10. Gastric cancer-derived exosomal miR-135b-5p impairs the function of Vγ9Vδ2 T cells by targeting specificity protein 1.
Li J; Sun L; Chen Y; Zhu J; Shen J; Wang J; Gu Y; Zhang G; Wang M; Shi T; Chen W
Cancer Immunol Immunother; 2022 Feb; 71(2):311-325. PubMed ID: 34159436
[TBL] [Abstract][Full Text] [Related]
11. Hypoxic Cancer-Secreted Exosomal miR-182-5p Promotes Glioblastoma Angiogenesis by Targeting Kruppel-like Factor 2 and 4.
Li J; Yuan H; Xu H; Zhao H; Xiong N
Mol Cancer Res; 2020 Aug; 18(8):1218-1231. PubMed ID: 32366676
[TBL] [Abstract][Full Text] [Related]
12. Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT.
Zhang X; Sai B; Wang F; Wang L; Wang Y; Zheng L; Li G; Tang J; Xiang J
Mol Cancer; 2019 Mar; 18(1):40. PubMed ID: 30866952
[TBL] [Abstract][Full Text] [Related]
13. ELK3 expressed in lymphatic endothelial cells promotes breast cancer progression and metastasis through exosomal miRNAs.
Kim KS; Park JI; Oh N; Cho HJ; Park JH; Park KS
Sci Rep; 2019 Jun; 9(1):8418. PubMed ID: 31182803
[TBL] [Abstract][Full Text] [Related]
14. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression.
Luo C; Xin H; Zhou Z; Hu Z; Sun R; Yao N; Sun Q; Borjigin U; Wu X; Fan J; Huang X; Zhou S; Zhou J
Hepatology; 2022 Oct; 76(4):982-999. PubMed ID: 35106794
[TBL] [Abstract][Full Text] [Related]
15. REX1 promotes EMT-induced cell metastasis by activating the JAK2/STAT3-signaling pathway by targeting SOCS1 in cervical cancer.
Zeng YT; Liu XF; Yang WT; Zheng PS
Oncogene; 2019 Oct; 38(43):6940-6957. PubMed ID: 31409905
[TBL] [Abstract][Full Text] [Related]
16. Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling.
Yu F; Liang M; Huang Y; Wu W; Zheng B; Chen C
J Exp Clin Cancer Res; 2021 Jun; 40(1):179. PubMed ID: 34074322
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3.
Liu W; Liu R; Yuan R; Wang X
Mol Biotechnol; 2021 Dec; 63(12):1268-1279. PubMed ID: 34386930
[TBL] [Abstract][Full Text] [Related]
19. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Ayala-Mar S; Donoso-Quezada J; González-Valdez J
J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
[TBL] [Abstract][Full Text] [Related]
20. MHC Class II Antigen Presentation by Lymphatic Endothelial Cells in Tumors Promotes Intratumoral Regulatory T cell-Suppressive Functions.
Gkountidi AO; Garnier L; Dubrot J; Angelillo J; Harlé G; Brighouse D; Wrobel LJ; Pick R; Scheiermann C; Swartz MA; Hugues S
Cancer Immunol Res; 2021 Jul; 9(7):748-764. PubMed ID: 33952631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
